Ciplox-TZ

Quick links to important sections

Ciplox-TZ

Method of action: Bactericidal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciplox-TZ

Property Description
Active ingredients Ciprofloxacin, Tinidazole
Form Tablet (Oral)
Pharmacological Class Antibiotic, Antiprotozoal Agent
Origin Synthetic
Type Combination Product

Ciplox-TZ is a powerful, synthetic combination product that functions as both an Antibiotic and an Antiprotozoal Agent. It is designed to be taken Orally in the form of a Tablet, offering a systemic approach to fighting specific infections throughout the body. Other common brands sharing this exact formulation include Esipflox Tz and Cifomed Tz.


What Type of Medicine is Ciplox-TZ? (Identity and Classification)

Ciplox-TZ is a unique, two-component medicine developed for systemic use against infections requiring broad coverage against diverse microbial life. It is classified as a synthetic antimicrobial, meaning it is entirely formulated using chemical synthesis rather than being naturally derived. This combination product integrates two distinct pharmacological classes to ensure comprehensive therapeutic action. Pharmacological studies support the necessity of using such a combination strategy when treating patients presenting with conditions where both bacterial and parasitic pathogens may be involved.


Composition: The Combination of Ciprofloxacin and Tinidazole

The medicine’s foundation rests upon two active ingredients with complementary actions: Ciprofloxacin and Tinidazole. Ciprofloxacin belongs to the Fluoroquinolone class of antibiotics, known for its bactericidal effect against various susceptible bacteria. Tinidazole is an Antiprotozoal Agent from the Nitroimidazole class, specifically targeting certain protozoa and bacteria that thrive in low-oxygen environments (anaerobes). Clinical data confirm that Fluoroquinolone agents are widely recognized for their broad activity against both Gram-positive and Gram-negative bacteria. The tablet form ensures precise delivery of both agents for systemic absorption.


General Purpose: Broad-Spectrum Dual Action

The general purpose of Ciplox-TZ is to combat mixed bacterial and parasitic infections that might not be fully eradicated by a single-component drug. The medicine provides broad-spectrum activity, a property clinically recognized for its effectiveness when treating conditions where multiple types of pathogens are common. The use of dual-action agents is a key strategy for treating complex infections where the exact pathogen is not yet identified or when multiple types are suspected. This strategy leverages the distinct mechanisms of the Fluoroquinolone and Nitroimidazole components to achieve a coordinated and comprehensive attack on the underlying cause of the infection.

What side effects are possible with Ciplox-TZ?

Possible Side Effects and Safety Information

The safety profile of this medicine is derived from the established risks associated with its two components, Ciprofloxacin (a Fluoroquinolone) and Tinidazole (a Nitroimidazole). Adverse reactions are formally classified by frequency and affected organ system, as documented in regulatory labeling.


Frequency and System-Organ Classes

The most frequently reported adverse events are categorized as Common. These typically involve the Gastrointestinal System (e.g., nausea, vomiting, diarrhea, abdominal pain) and the Nervous System (e.g., headache, dizziness, metallic taste). Adverse effects are generally grouped across major systems, including Musculoskeletal, Hepatobiliary, Blood and Lymphatic, and Skin disorders.


Serious and Clinically Significant Reactions

Official regulatory documents highlight the potential for Serious Adverse Reactions, which are often rare but clinically significant. These include disabling and potentially irreversible effects such as Tendon Disorders (tendinitis and rupture) and Peripheral Neuropathy. Other serious events include severe Hepatotoxicity (hepatic failure), Clostridioides difficile-associated diarrhea (CDAD), and the risk of QT prolongation which can affect heart rhythm.


Population-Specific Constraints

Specific limitations exist for certain groups. The medicine is not generally recommended for pediatric patients due to the risk of joint cartilage damage. Use is contraindicated during the first trimester of pregnancy and during breastfeeding. Furthermore, consumption of alcohol is strictly prohibited during treatment and for a specified period after the final dose to prevent a severe systemic reaction. Certain serious reactions, such as tendon disorders, can occur hours after starting therapy or be delayed for months after cessation.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Ciplox-TZ (Ciprofloxacin and Tinidazole) by its documented potential for severe organ toxicity. Manifestations include pronounced Central Nervous System (CNS) effects, such as confusion, agitation, hallucinations, and the critical risk of convulsive seizures. Overdose may also present with severe gastrointestinal symptoms like nausea and vomiting, and neurological disturbances, such as ataxia and the onset of peripheral neuropathy. A critical documented risk is acute renal failure and crystalluria (crystals in the urine), linked to the Ciprofloxacin component.

Immediate regulatory guidance mandates that patients seek emergency medical attention or call a Poison Help line for any suspected overdose. Clinical management is required to be symptomatic and supportive; official documents explicitly state that no specific antidote is known for the Tinidazole component. Monitoring procedures include continuous ECG monitoring due to the potential for QT interval prolongation, and close renal function monitoring is necessary due to the risk of kidney injury. The maintenance of adequate hydration is required to mitigate the risk of crystalluria.

Population-specific regulatory notes indicate the Tinidazole component is easily dialyzable and the risk of severe hypoglycemia is reported to occur more frequently in the elderly population.

Therapeutic Uses of Ciplox-TZ

What Ciplox-TZ Treats: Main Uses and Benefits

The core therapeutic domain of this combination medicine involves its use in situations involving certain distressing symptoms. The medicine is broadly applied across domains where additional symptomatic support is needed, helping to manage symptoms that interfere with daily comfort. It is commonly used across conditions presenting with acute episodes and where symptoms may intensify temporarily.


Easing Acute Symptom Burdens

Ciplox-TZ is generally used across various clinical scenarios to address symptom clusters that may become intense or disruptive and appear suddenly or intensify quickly. It provides support that helps ease the overall symptom burden and offers symptomatic relief. This is relevant in contexts marked by increased discomfort or tension, relevant in situations where symptoms lead to temporary functional strain or discomfort.


Stabilizing Functional Discomfort

Commonly used across conditions characterized by periods of heightened symptoms, this treatment is relevant in clinical settings that involve acute or unstable symptom patterns where short-term symptomatic assistance is needed. It may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Supportive Management for Acute Symptoms

Ciplox-TZ is used when groups of symptoms appear suddenly or fluctuate, and may help manage the overall symptom load during difficult episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ciplox-TZ?

The eligibility for Ciplox-TZ (Ciprofloxacin and Tinidazole) is determined by formal restrictions documented in authoritative government regulatory sources. Use is primarily established for Adults who do not have documented contraindications.


Contraindicated Populations

Use is strictly prohibited for patients with a known hypersensitivity (allergy) to Ciprofloxacin (or any Fluoroquinolone), Tinidazole (or any Nitroimidazole), or any component of the tablet. The medicine is also contraindicated for women in the first trimester of pregnancy and for nursing mothers (requiring interruption of breastfeeding).

Furthermore, patients with Myasthenia Gravis, a history of blood dyscrasia, or a history of tendon disorders related to previous Quinolone treatment must not use this medicine. Concomitant use with Tizanidine is also formally prohibited.


Conditional and Restricted Use

Population/Condition Eligibility Status
Children and Adolescents Use Generally Not Recommended; reserved for specific, severe infections due to arthropathy risk.
Renal or Hepatic Impairment Use with Caution; monitoring and possible dosage adjustment required.
Older Adults Use with Caution; increased risk of tendon disorders and age-related decline in organ function.
Seizure Risk/CNS Disorders Use with Caution; may lower the seizure threshold.

What should I know about interactions with other medicines?

The official regulatory information for Ciplox-TZ is defined by the interaction patterns of its active components, Ciprofloxacin and Tinidazole. Certain combinations are formally contraindicated: co-administration with Tizanidine is prohibited due to the risk of potentiated hypotensive and sedative effects. Additionally, due to the Tinidazole component, alcohol and alcohol-containing products must be avoided during therapy and for at least 72 hours after the final dose to prevent a disulfiram-like reaction.

Pharmacokinetic Interactions: Ciprofloxacin is documented as an inhibitor of the CYP1A2 enzyme, which can lead to increased systemic exposure and reduced clearance of co-administered medicines that are metabolized by this pathway, such as Theophylline. Products containing multivalent cations (e.g., antacids, iron, or zinc supplements) significantly reduce Ciprofloxacin absorption by chelation. A mandatory timing separation is required, meaning these products must be administered at least 2 hours before or 6 hours after Ciplox-TZ.

Pharmacodynamic Interactions: The Tinidazole component potentiates the effects of oral anticoagulants like Warfarin, which is officially described as a prolongation of prothrombin time. Co-administration of Ciprofloxacin with corticosteroids is associated with an increased risk of tendinitis and tendon rupture. Drugs that prolong the QT interval should be avoided due to the potential for additive proarrhythmic effects.

Mechanism of Action

How Ciplox-TZ Works

Ciplox-TZ acts via a complementary dual-action mechanism that disrupts the fundamental genetic processes of susceptible pathogens.

Ciprofloxacin: Genomic Disruption of Aerobic Bacteria

The Ciprofloxacin component targets essential bacterial enzymes, primarily DNA Gyrase (Topoisomerase II) and Topoisomerase IV. By binding to and stabilizing the transient enzyme-DNA complex, Ciprofloxacin acts as a Quinolone Poison, blocking the enzymes from resealing the cleaved DNA strands. This interference leads to the accumulation of irreparable double-strand DNA breaks, which is a direct bactericidal consequence, leading to the forced microbial cell death.

Tinidazole: Toxic Radical Activation in Anaerobes and Protozoa

The Tinidazole component requires a specific biological environment for activation. Upon entering the pathogen, the prodrug is reduced by low-redox potential enzymes, transforming it into toxic nitro radicals. These radicals chemically damage and fragment the microbial DNA, impairing genetic function and leading directly to cell death (protozoacidal/anaerobicidal effect). This mechanism is selective; most aerobic organisms lack the necessary low-redox potential systems for prodrug activation.

Mechanistic Synergy for Comprehensive Coverage

The combination leverages mechanistic complementarity to achieve broad-spectrum clearance: Ciprofloxacin handles the DNA maintenance of organisms thriving in aerobic environments, while Tinidazole chemically destroys the DNA of organisms confined to anaerobic environments. This dual-action approach contributes to the reduction of the total viable microbial load across diverse pathogen types through coordinated genetic disruption.

Dosage and Administration Information

The combination product Ciprofloxacin 500 mg and Tinidazole 600 mg is administered via the oral route as a tablet. The established standard dosing regimen for adults involves taking one tablet twice daily at approximately 12-hour intervals to maintain consistent systemic concentrations of both agents. The typical duration of use ranges from 5 to 14 days, based on the protocol defined for the condition being treated.

For proper administration, the tablet must be swallowed whole with a full glass of water and is not intended to be crushed, chewed, or broken. The tablet should be taken 1 hour before or 2 hours after a meal to optimize drug levels, although taking it with food is permitted to help minimize gastrointestinal discomfort. Avoidance is mandated for concurrent ingestion with dairy products (such as milk or yogurt) and calcium-fortified juices, as calcium can significantly reduce the absorption of the Ciprofloxacin component.

A critical administration constraint involves alcohol: the consumption of alcohol must be strictly avoided for the entire duration of the course and for a minimum of three days following the final dose due to the Tinidazole component.

Regarding patient-specific use, the medicine is not recommended for the pediatric population. Prescribing information indicates that dose adjustments are necessary for adult patients presenting with severe renal or hepatic impairment. If a scheduled dose is missed, the protocol is to take it as soon as it is remembered; however, if the next scheduled dose is nearly due, the missed dose is omitted to prevent the administration of two doses too close together.

Recent Clinical Evidence

Recent Clinical Evidence

Ciplox-TZ is a combination antimicrobial medication containing ciprofloxacin (a fluoroquinolone antibiotic) and tinidazole (an antiprotozoal agent). This fixed-dose combination is used to address infections suspected to be caused by a mix of susceptible bacteria and protozoa or anaerobic microorganisms.

Scope of Research

Clinical studies involving the ciprofloxacin-tinidazole combination have explored its use across a variety of infection types, primarily focusing on conditions where both aerobic and anaerobic/protozoal pathogens may be present. This includes:

  • Gastrointestinal Infections: Research has examined the effects of this combination therapy in managing complex abdominal infections, such as certain types of severe diarrhea or dysentery, due to the need to target a wide range of causative agents.
  • Gynecological and Pelvi-abdominal Infections: Studies have evaluated the combination's use in mixed infections affecting the pelvic and reproductive organs.
  • Skin and Soft Tissue Infections: Clinical data exists from trials that investigated the use of this drug combination in treating certain complicated skin and soft tissue infections.

Clinical Findings Overview

Area of Investigation Study Findings Focus
Efficacy Trial reports show the combination's ability to reduce pathogen load and achieve favorable clinical and microbiological responses in a majority of patients studied.
Safety Profile Adverse events most frequently noted in trials included gastrointestinal issues like nausea, vomiting, a metallic taste, and headache. Serious side effects, though rare, are monitored and reported in trial data.

Comparative studies have explored the effectiveness of the ciprofloxacin-tinidazole combination against older mono-therapies in specific refractory infections, suggesting a difference in outcomes for some patient groups. Due to the broad activity profile, this combination is typically reserved for complex infections or those that have not responded to a single antimicrobial agent.

Key Studies & References

  1. Ciprofloxacin (StatPearls - NCBI Bookshelf) - General Information and Mechanism

Frequently Asked Questions (FAQ)

Common questions about Ciplox-TZ (FAQ)

Q: Is it normal to feel dizzy or nauseous on Ciplox-TZ?

According to official product information, nausea (feeling sick), vomiting, and dizziness are reported as common side effects of this medication. These are among the adverse reactions frequently noted in clinical trials. If these effects are severe or persistent, it is important to consult a healthcare professional.


Q: Can I take Ciplox-TZ if I'm also taking common painkillers like ibuprofen?

Official product information suggests caution regarding potential interactions with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common painkillers like ibuprofen. Interactions involving the ciprofloxacin component and NSAIDs are noted in regulatory documents.


Q: Can Ciplox-TZ cause changes in sleep patterns?

Yes, official reports for the ciprofloxacin component list insomnia (difficulty sleeping) and nightmares as possible Central Nervous System (CNS) side effects. Patients should be aware of the possibility of these changes in their sleep patterns while using this medication.


Q: Is it okay to drink milk or have dairy products with Ciplox-TZ?

Official guidance mandates the avoidance of taking the tablet at the same time as dairy products (such as milk or yogurt) or calcium-fortified juices. This is because calcium can significantly reduce the absorption of the ciprofloxacin component, potentially reducing the medication's effectiveness.


Q: Can Ciplox-TZ make my skin more sensitive to the sun?

Yes, the ciprofloxacin component can cause photosensitivity reactions. This means that exposure to sunlight or ultraviolet (UV) light may lead to an exaggerated sunburn-like reaction. Official warnings advise minimizing or avoiding sun exposure while taking the medication.


Q: What happens if I stop taking Ciplox-TZ before the full course is finished?

Official information strongly discourages stopping antibiotic courses early. Not completing the full prescribed duration may increase the risk of the infection recurring and can contribute to the development of drug-resistant bacteria.


Q: Do I need to eat a full meal when taking Ciplox-TZ?

The tablet is generally recommended to be taken 1 hour before or 2 hours after a meal to optimize drug absorption. Taking it with food is permitted by official guidelines, primarily to help minimize potential gastrointestinal discomfort.


Q: Can Ciplox-TZ cause thrush or yeast infections?

Yes, regulatory documents note that this drug is associated with the risk of superinfections. These occur when the medication eliminates healthy bacteria, potentially allowing other organisms, such as fungi or yeast (which cause thrush), to overgrow.


Q: What is the difference between Ciplox-TZ and Ciprofloxacin alone?

Ciprofloxacin alone contains only the single antibiotic agent from the fluoroquinolone class. Ciplox-TZ is a combination product that contains Ciprofloxacin plus Tinidazole, an antiprotozoal agent. This combination is designed to provide broader coverage against both aerobic bacteria and anaerobic/protozoal pathogens.


Q: Can Ciplox-TZ be used for a normal cold or flu?

No. Official regulatory documents specify that this medicine is an antibiotic/antiprotozoal product. It is intended only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria or protozoa. It is not indicated for the treatment of viral infections, such as the common cold or flu.


Q: Is Ciplox-TZ safe for older adults (seniors)?

While use in older adults is permitted, official information warns that this population is at an increased risk of certain severe adverse reactions, most notably tendon disorders. Clinical monitoring may be necessary for these patients.


Q: How long does Ciplox-TZ stay in the system after the last pill?

The elimination half-life of the ciprofloxacin component is approximately 4 to 5 hours, while the tinidazole component is longer (12 to 14 hours). Based on the half-life information, it generally takes an extended period for the medication to be fully eliminated from the body.


Q: How is Ciplox-TZ different from Flagyl (metronidazole)?

Flagyl is a brand name for the drug Metronidazole. Ciplox-TZ is a combination drug containing Ciprofloxacin (an antibiotic) and Tinidazole (an agent related to Metronidazole). The combination product provides broad coverage against more pathogen types than Metronidazole alone.


Q: Is there a generic version of Ciplox-TZ available?

Yes, official labeling notes that in addition to the brand name Ciplox-TZ, there are other brand names and generic versions that contain the exact same fixed combination of ciprofloxacin and tinidazole.


Q: Does Ciplox-TZ affect liver function tests?

Official adverse event reports list abnormal liver function tests as a possible reaction observed during clinical studies. The presence of these changes is a finding noted in the regulatory documents.


Q: Is Ciplox-TZ used to treat stomach infections?

The drug is indicated for specific, complicated intra-abdominal infections. This term covers severe infections affecting areas of the abdomen, though it is generally reserved for conditions where both bacterial and anaerobic/protozoal pathogens are suspected.


Q: Can Ciplox-TZ cause temporary changes to vision?

Official post-marketing experience for the ciprofloxacin component has reported cases of visual disturbances. This information is documented in the safety profile of the medication.


Q: Does Ciplox-TZ have any known long-term side effects?

Yes, official warnings highlight that serious adverse reactions, such as tendon rupture or peripheral neuropathy (nerve damage), can be disabling and potentially irreversible. These effects may occur hours after starting the drug or be delayed for months after stopping the medication.


Q: Can men use Ciplox-TZ for common infections?

The drug is indicated for use in adults, both male and female, for susceptible infections. Regulatory documentation specifically lists chronic bacterial prostatitis as one of the conditions for which the drug is indicated in men.


Q: Is Ciplox-TZ effective against fungal infections?

No. Official documents classify the active ingredients as an antibiotic and an antiprotozoal agent. Their mechanisms of action are designed to target bacteria and protozoa, and they are generally not effective against fungal organisms.


Q: Why do some people feel a metallic taste in their mouth with this medication?

Official product information lists a metallic taste as a commonly reported adverse reaction. This side effect is primarily associated with the tinidazole component, which is similar to other drugs in the nitroimidazole class.


Q: Can I drive or operate machinery while taking Ciplox-TZ?

Due to the potential for Central Nervous System (CNS) side effects like dizziness and confusion, caution is advised before performing activities requiring full mental alertness, such as driving or operating machinery. This warning is based on official safety information.


Q: Is Ciplox-TZ used for dental or gum infections?

The drug is active against the types of pathogens (anaerobic bacteria and protozoa) that often cause severe oral or deep tissue infections. While not explicitly listed for simple cases, its broad activity profile makes it a consideration for complex infections where those pathogens are involved.


Q: Are there any common over-the-counter drugs that should be avoided with Ciplox-TZ?

Yes, the absorption of ciprofloxacin is significantly reduced by products containing multivalent cations. This includes common over-the-counter products such as antacids and mineral supplements containing iron or zinc, which should be separated from your dose by several hours.


Q: Does Ciplox-TZ cause antibiotic resistance if misused?

Official warnings state that use in the absence of a proven or strongly suspected bacterial or protozoal infection may increase the risk of developing drug-resistant bacteria. This highlights the importance of using antibiotics only as indicated.

How should Ciplox-TZ be stored and disposed of?

Official Storage and Disposal Instructions for Ciplox-TZ

Official regulatory guidelines for Ciplox-TZ (Ciprofloxacin/Tinidazole) require strict adherence to environmental and handling constraints to ensure product stability.

Condition Type Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Must be kept out of the sight and reach of children and protected from light and moisture.
Handling Do not freeze. Keep in the original container, tightly closed, and avoid damp areas like bathrooms.
Disposal Do not flush unused or expired tablets down the toilet or drain. Utilize official drug take-back programs or follow specific government disposal guidelines for safe discarding.

These requirements maintain the integrity of the active ingredients and prevent environmental contamination, as mandated by health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciplox-TZ found in:

A-Z Index: